The ACR has continued its advocacy to ensure the safe adoption of biosimilars in the U.S., most recently addressing an FDA public hearing. Also, the FDA has approved tofacitinib for RA, and a clinical trial of romosozumab for patients with osteoporosis met its primary endpoint…
Search results for: postmenopausal osteoporosis
Do Bisphosphonates Increase Risk of Carpal Tunnel Syndrome?
In a large-scale study, researchers demonstrated that the use of bisphosphonates in postmenopausal women is associated with an increased risk of carpal tunnel syndrome, in addition to other known risks (e.g., incapacitating bone, joint and/or musculoskeletal pain, and osteonecrosis of the jaw)…
Denosumab Does Not Stimulate Early Bone Formation
NEW YORK (Reuters Health)—The early elevation in intact parathyroid hormone (iPTH) seen with denosumab treatment is not associated with increased bone formation, according to research from Eli Lilly and Company. Denosumab is a member of the anticatabolic/antiresorptive class of drugs used to treat osteoporosis; iPTH levels are increased in the first several months after denosumab…
Understanding the Z Codes in ICD-10
Two months into the transition, the ICD-10 code set is still not exactly the most enticing reading material. But there is still so much to learn and apply, that it is necessary for physicians, coders and billers to stay abreast of the coding and billing guidelines. Although all of the guidelines and conventions may be…
Bone Turnover Markers Show Link to Iliac Histomorphometry in Older Women
NEW YORK (Reuters Health)—Although histomorphometry of iliac bone gives precise results, bone turnover markers provide a better reflection of the overall skeleton in untreated postmenopausal osteoporotic women, according to French researchers. Bone histomorphometry allows study of bone remodeling at the basic structural unit level, Dr. Pascale Chavassieux and colleagues at the University of Lyon note…
New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising
The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…
Vitamin D in Rheumatology: Cause and Effect Unclear
The controversy over vitamin D is hearty enough to confuse even seasoned rheumatologists, says Nathan Wei, MD, The Arthritis Treatment Center, Frederick, Md. “It’s like what you hear with coffee. One week, [a study finds] coffee is … good for you; the next week, there’s a study saying it’s bad for you,” he says. Vitamin…
HIV Infection: What Rheumatologists Need to Know
It has been nearly 35 years since the original descriptions of what now is recognized as AIDS (the acquired immune deficiency syndrome), an advanced form of infection secondary to the human immunodeficiency virus (HIV). The epidemic of HIV infection remains the singular most dramatic epidemic of our generation and will likely remain with us for…
Coding Corner Answers: January
Proper coding for cases of drug-induced gout, systemic lupus erythematosus with lung involvement, inflammatory rheumatoid arthritis, osteoporosis
Persistent Symptomatic Hypocalcemia Due to Denosumab: A Case Review
Patients with osteoporosis and impaired renal function are at risk